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A substantial proportion of the familial risk of breast cancer may be attributable to genetic variants each contributing a small effect.
pRb controls the cell cycle and polymorphisms within it are candidates for such low penetrance susceptibility alleles, since the gene
has been implicated in several human tumours, particularly breast cancer. The purpose of this study was to determine whether
common variants in the RB1 gene are associated with breast cancer risk. We assessed 15 tagging single-nucleotide polymorphisms
(SNPs) using a case–control study design (np4474 cases and np4560 controls). A difference in genotype frequencies was found
between cases and controls for rs2854344 in intron 17 (P-trend¼0.007) and rs198580 in intron 19 (P-trend¼0.018). Carrying the
minor allele of these SNPs appears to confer a protective effect on breast cancer risk (odd ratio (OR)¼0.86 (0.76–0.96) for
rs2854344 and OR¼0.80 (0.66–0.96) for rs198580). However, after adjusting for multiple testing these associations were
borderline with an adjusted P-trend¼0.068 for the most significant SNP (rs2854344). The RB1 gene is not known to contain any
coding SNPs with allele frequencies X5% but several intronic variants are in perfect linkage disequilibrium with the associated SNPs.
Replication studies are needed to confirm the associations with breast cancer.
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Breast cancer is the most common cancer in women worldwide
and women in the UK have a one out of 10 lifetime risk of
developing the disease. First-degree female relatives of breast
cancer patients have an approximately two-fold increased risk over
the general population, but less than 25% of this excess risk is
explained by inherited mutations in known high penetrance breast
cancer susceptibility genes, such as BRCA1 and BRCA2 (Antoniou
et al, 2001). Data from large multiple case families suggest that
there will be few other high penetrance genes. It is more plausible
that there are multiple common low risk (low penetrance) genetic
variants, which are associated with relatively small effects on risk
in the individual, but contribute substantially to the overall risk in
the population (Antoniou et al, 2002).
Controlling the progression of cells into and through Sphase of
the cell cycle is important in regulating DNA synthesis and thus
cell proliferation. The retinoblastoma protein (pRb) is critical for
regulating not only progression of cells from G1 into Sphase, but
also progression of cells through Sphase (Weinberg, 1995;
Knudsen et al, 1998; Niculescu et al, 1998). It acts as a negative
regulator of cellular proliferation by sequestering a variety of
nuclear proteins involved in cellular growth that are released when
pRb is phosphorylated. The gene RB1, encoding the protein, was
mapped to chromosome 13q14.12–13q14.2 in children who
developed retinoblastoma, a rare cancer of the eye, and was the
first tumour-suppressor gene to be cloned (Friend et al, 1986). It
consists of 27 exons that are distributed over 180kb. Mutations are
spread across the gene and approximately 80% of patients with
hereditary mutations have bilateral disease. Hereditary retinoblas-
toma patients are at risk of developing and dying of second
primary cancers in childhood and adolescence (Francois et al,
1980; Draper et al, 1986; Lueder et al, 1986; DerKinderen et al,
1988; Olsen et al, 1990) and excess mortality from second
malignancies in retinoblastoma survivors was found to persist
during long-term follow-up into adulthood. Female patients have a
higher mortality from second tumours (RR¼39) than males
(RR¼22) (Eng et al, 1993). Germline mutations in specific codons
or regions of the RB1 gene could therefore predispose to the
development of a second tumour. Subsequent studies have shown
somatic mutation of RB1 in a variety of cancers, including
sarcomas, breast cancer, lung cancer and genitourinary cancers
(Benedict et al, 1988; T’Ang et al, 1988; Hensel et al, 1990; Sasano
et al, 1990). Common variants in RB1 are therefore candidate for
low to moderate risk breast cancer alleles.
Association studies, using very large sets of affected cases and
suitably selected controls, are considered to be the most powerful
method for finding common low penetrance disease susceptibility
genes. The aim of this study was to test the hypothesis that one or
more variants in the gene is associated with breast cancer using a
single-nucleotide polymorphism (SNP) tagging approach in a
large, British breast cancer case–control study. In order to have
good power to detect small relative risks we have restricted our
attention to common SNPs and haplotypes (frequency X5%).
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Patients and controls
Cases were drawn from SEARCH (breast), an ongoing population
based study, with cases ascertained through the East Anglian
Cancer Registry. All patients diagnosed with invasive breast cancer
below age 55 years since 1991 and still alive in 1996 (prevalent
cases, median age 48 years), together with all those diagnosed o70
years between 1996 and the present (incident cases, median age 54
years) were eligible to take part. In all, 67% of eligible breast cancer
patients returned a questionnaire and 64% provided a blood
sample for DNA analysis. Controls were randomly selected from
the Norfolk component of European Prospective Investigation of
Cancer (EPIC). European Prospective Investigation of Cancer is a
prospective study of diet and cancer being carried out in nine
European countries. The EPIC-Norfolk cohort comprises 25000
individuals resident in Norfolk, East Anglia) – the same region
from which the cases have been recruited. Controls were not
matched to cases, but were broadly similar in age, being aged
42–81 years old at blood draw (median age 63 years). The ethnic
background of both cases and controls as reported on the
questionnaires was similar, with 498% being white. The study
was approved by the Eastern Region Multicentre Research Ethics
Committee, and all patients gave written informed consent.
The total number of cases available for analysis was 4474 of
whom 27% were prevalent cases. The samples have been split into
two sets in order to save DNA and reduce genotyping costs: the
first set (n¼2271 cases and 2280 controls) is genotyped for all
SNPs and the second set (n¼2203 cases and 2280 controls) is then
tested for those SNPs that show marginally significant associations
in set 1 (P-heterogeneity or P-trend o0.1). This staged approach
substantially reduces genotyping costs without significantly
affecting statistical power. Cases were randomly selected for set 1
from the first 3500 recruited, with set 2 comprising the remainder
of these plus the next 974 incident cases recruited. As the prevalent
cases were recruited first, the proportion of prevalent cases was
somewhat higher in set 1 than set 2 (33 vs 20%). Median age at
diagnosis was similar in both sets (51 and 52 years old,
respectively). There was no significant difference in the morph
ology, histopathological grade or clinical stage of the cases by set
or by prevalent/incident status.
Identification of SNPs
Single-nucleotide polymorphisms were initially identified through
the following SNP databases: ENSEMBL, http://www.ensembl.org/,
dbSNP, http://www.ncbi.nlm.nih.gov/SNP, and The RB1 gene
mutation database, http://www.d-lohmann.de/Rb/polym_t2.html
(Lohmann, 1999). Eleven SNPs, encompassing the RB1 gene and
with a reported frequency X5% in the Caucasian population
according to the public databases were initially examined in a set
of 96 individuals from the EPIC-Norfolk population in order to
confirm their presence in the British population (Table 1) and to
estimate pairwise correlation coefficients (rp
2). Two SNPs, rs198610
and rs198580 were subsequently found to have a frequency lower
than 5% in our East Anglian sample set. Strong linkage
disequilibrium (LD) across the RB1 gene was observed (illustrated
by r
2 values shown in Table 1).
During the course of the study the NIEHS EGP Project (http://
pga.gs.washington.edu/finished_genes.html) released resequencing
Table 1 Selection of SNPs across RB1
SNP ID
Genomic
location
Nucleotide
change
a
SNPs chosen initially
for genotyping
SNP reported by NIEHS
with MAF40.05 Tag SNP Tagging SNP(s) rp
2
rs1573601 Upstream c4a | rs1981434, rs4151540,
rs3092904 (g/+/a
haplotype)
0.93
rs1981434 Intron 1 c4g || rs1981434 1.0
rs2854345 Intron 2 a4g || | rs2854345 1.0
rs4151437 Intron 2 g4a | rs4151551 0.80
rs4151438 Intron 2 c4g | FAIL
b rs2854345 0.19
rs520342 Intron 3 c4t || | rs520342 1.0
rs4151450 Intron 3 g4c | rs399413 0.85
rs198619 Intron 7 t4a | rs399413 0.84
rs4151510 Intron 11 g4a | rs4151620 1.0
rs4151520 Intron 11 g4a | rs520342 0.96
rs399413 Intron 12 g4a || | rs399413 1.0
rs4151540 Intron 17 -4aa || rs4151540 1.0
rs198610 Intron 17 g4t | ?
c ?
rs4151551 Intron 17 g4t || rs4151551 1.0
rs2227311 Intron 17 t4c || | rs4151620 1.0
rs2854344 Intron 17 g4a | ?
c ?
rs9535032 Intron 17 a4g | ?
c ?
rs425834 Intron 17 a4g || rs425834 1.0
rs1951775 Intron 17 g4t | rs399413 0.85
rs198570 Intron 17 g4t | rs3092904 1.0
rs4151580 Intron 18 g4a | Not polym
d rs4151580 1.0
rs4151584 Intron 18 t4c | FAIL
b rs2854345 0.28
rs198580 Intron 19 a4g | ?
c ?
rs198590 Intron 21 g4a | rs520342 1.0
rs4151611 Intron 24 g4a || rs4151611 1.0
rs4151618 Intron 24 t4c | rs4151611 1.0
rs4151620 Intron 24 c4g || | rs4151620 1.0
rs3092904 Intron 24 t4a || | rs3520342 0.98
rs4151636 Downstream c4g || rs4151636 1.0
aThe most common allele is given first.
bThe SNP was initially selected for genotyping but the assay could not be designed.
cThe contribution of the SNP to the tagging of other
identified SNP could not be estimated.
dThe SNP was not polymorphic in the British population.
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the genomic sequence. Data were available for a panel of 90
individuals representative of US ethnicities: including 24 European
Americans, 24 African Americans, 12 Mexican Americans, 6 Native
Americans and 24 Asian Americans (PDR90) (Livingston et al,
2004). It is known that there is greater genetic diversity in
individuals of African origin but ethnic group identifiers for the
PDR90 samples are not available. We identified 28 of the samples
most likely to be African-American in this population by
comparing the genotypes for the PDR90 samples with the
genotypes for the same SNPs from the National Heart, Lung, and
Blood Institute Variation Discovery Resource project African-
American panel. Data from the remaining 62 individuals were used
to identify a set of tagging SNPs (stSNPs). Of 279 SNPs identified
in the PDR90 samples, only 25 are likely to have a frequency X0.05
in Caucasians (Table 1).
We used the programme Tagger to select a set of SNPs to tag all
the known common variants (Paul de Bakker, http://www.broad.
mit.edu/mpg/tagger). Tagger uses a strategy that combines the
simplicity of pairwise methods with the potential efficiency of
multimarker approaches. It begins by selecting a minimal set of
markers such that all alleles to be captured are correlated at an rp
2
greater than 0.8 with a marker in that set. It then tries to capture
SNPs which could not be captured in the pairwise step using
multimarker tests constructed from the set of markers chosen as
pairwise tags.
Four of the SNPs we had initially chosen were not present in the
PDR90 data set (all in intron 17). The remaining seven were forced
in as tagging SNPs. An additional eight tagging SNPs were chosen,
but an assays could not be designed for two of these, neither of
which had alternative tags. Another tSNP was found not to be
polymorphic in our population. Thus, 12 tSNPs were genotyped in
our case–control sample. These tagged 22 out of 25 SNPs with
rp
240.8 and one SNP (rs1573601) was tagged by a three SNP
haplotype combination. The SNPs which failed assay design were
tagged with rp
2 ¼0.19 and rp
2 ¼0.28. The contribution of the four
additional SNPs identified through public databases to the tagging
of other known variants could not be estimated.
Genotyping
We genotyped all samples for the 15 SNPs using the ABI PRISM
7900 sequence detection system or ‘Taqman’ (Applied Biosystems,
Foster City, CA, USA). Forward and reverse primers, and FAM and
VIC labelled probes were designed by Applied Biosystems (ABI
Assays-by-Design or ABI Assays-on-Demand). Sequences for
primers and probes are available on request. We carried out
PCR on DNA (10ng) using TaqMan universal PCR master mix
(Applied Biosystems) in a 5ml reaction. Amplification conditions
on MJ Tetrad thermal cyclers (GRI) were as follows: one cycle of
951C for 10min, followed by 40 cycles of 951C for 15s and 601C for
1min. We read the completed PCRs on an ABI PRISM 7900
Sequence Detector in end point mode using the Allelic Discrimi-
nation Sequence Detector Software (Applied Biosystems). For the
software to recognise the genotypes, we included two nontemplate
controls in each 384-well plate. For set 1 and set 2, cases and
controls were arrayed together in twelve 384-well plates and a
thirteenth plate contained eight duplicate samples from each of the
twelve plates to insure a good quality of genotyping. For each SNP,
failed genotypes were not repeated.
Statistical methods
For each polymorphism, deviation of the genotype frequencies
from those expected under Hardy–Weinberg equilibrium was
assessed in the controls by w
2 tests. Genotype frequencies in cases
and controls were compared by w
2 tests (P-heterogeneity, 2d.f.).
We also tested for an allele dose effect assuming a multiplicative
codominant model using unconditional logistic regression
(P-trend, 1d.f.). The genotypic specific risks were estimated as
odds ratios (ORs) with associated 95% confidence limits. For SNPs
that were significant at the 5% level we also compared the fit of
dominant and recessive models with the codominant model by
combining the appropriate genotype categories.
In addition to the univariate analyses we carried out global
haplotype test and a specific haplotype test for a three SNP
haplotype that tagged a common variant. Haplotype frequencies
and subject-specific expected haplotype indicators were calculated
separately using the programme TagSNPs, which implements
an expectation-substitution approach to account for haplotype
uncertainty given unphased genotype data (Stram et al, 2003a,b).
Subjects missing more than 50% genotype data were excluded
from haplotype analysis. We considered haplotypes with greater
than 4% frequency in either cases or controls to be ‘common’. Rare
haplotypes were pooled. We used unconditional logistic regression
to test the global null hypothesis of no association between
haplotype frequency and breast cancer, by comparing a model with
multiplicative effects for each common haplotype (treating the
most common haplotype as referent) to the intercept-only model.
Haplotype-specific ORs were also estimated with their associated
confidence intervals.
Screening of the P2RY5 gene
We looked for the presence of polymorphisms with rare allele
frequency X5% in the P2RY5 gene (RefSeq NT_024524) in our
population by sequencing a set of 48 genomic DNA samples from
the UK breast cancer patients. Sequencing was performed on the
ABI Prism 3100 Capillary DNA Sequencer (Applied Biosystems)
according to the manufacturer recommendations. The pairs of
primers used for the sequencing of the P2RY5 gene are available
from authors on request.
RESULTS
Association analysis of SNPs
Genotype distributions in the controls did not differ significantly
from those expected under Hardy–Weinberg equilibrium for any
of the SNPs. Of the 15 SNPs, 12 were genotyped only in set 1. SNPs
rs2854344 and rs4151611 were tested in set 2 because they met the
threshold for significance (see methods) and rs198580 was also
tested in set 2 because we had observed a borderline association
for this SNP with another disease phenotype (data not shown).
There was no significant difference in genotype frequencies
between cases and controls for SNPs rs1981434, rs2854345,
rs520342, rs399413, rs4151540, rs198610, rs2227311, rs9535032,
rs425834, rs4151611, rs4151620, rs3092904 and rs4151636 (Table 2).
For two SNPs, rs2854344 and rs198580, unadjusted P-values for
comparison of genotype distribution between cases and controls
were below the 5% level (P-heterogeneity¼0.02 and 0.03 and
P-trend¼0.007 and 0.018, respectively). Genotype-specific risks
for all tagging SNPs are in Table 2. There was no association in
controls between age and genotype frequency for any of the SNPs,
and age-adjusted genotype-specific ORs were similar to the
unadjusted ORs (data not shown). The minor allele of rs2854344
appeared to confer a reduced risk of disease with a dominant
model fitting the data slightly better than the codominant one
(P¼0.006 vs 0.007). The dominant model also fit the data best for
rs198580 (P¼0.01 vs 0.02), also with a protective effect of the
minor allele, even though the risk estimate for rare homozygous
individuals was 1.4 (0.31–6.24).
One SNP, rs1573601, was tagged by the haplotype consisting of
the three rare alleles of rs1981434, rs4151540 and rs3092904. The
frequency of this haplotype was similar in cases (0.25) and in
controls (0.25) (P¼0.94).
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As the complete gene was not resequenced, it is possible that
important functional variants that have not been tagged by the 15
SNPs genotyped could have been missed. We therefore carried out
a comparison of common haplotype frequencies in cases and
controls in addition to the univariate and specific three SNP
haplotype analyses. There were five common haplotypes which
accounted for 84% of all haplotypes in the control population
(Table 3). We found no evidence of differences in common
haplotype frequencies between cases and controls (P¼0.08, 5df).
Table 3 shows the haplotype-specific ORs, none of which differed
significantly from the unity.
Exclusion of the P2RY5 gene
The SNP rs2854344 lies in intron 17 of RB1, which at 72kb is the
largest intron of the gene. The intron contains an open reading
frame encoding the G protein-coupled receptor P2RY5 (Purinergic
Receptor P2Y, G-protein coupled, 5) in the reverse orientation
relative to the transcription of RB1 (Herzog et al, 1996). The P2RY5
gene consists of only one coding exon and rs2854344 lies 11kb 50 of
this exon. Various bioinformatic tools (NIX, Nucleotide Identify
X software, http://www.hgmp.mrc.ac.uk/NIX; PupaSNP, http://
pupasnp.bioinfo.cnio.es) suggest that the variant rs2854344 (and
the variant rs198580 in intron 19 of RB1) does not have any
functional effect, or alter dramatically the structure of RB1 or of
P2RY5 (data not shown). Therefore, causal variant(s) in LD with
rs2854344 and rs198580 could be located within RB1 or within
P2RY5. In order to investigate a possible association with variants
within P2RY5, we sequenced the unique exon of P2RY5 and 500bp
of its flanking sequences in 50 and 30 in a panel of 48 controls. No
coding SNP was identified. The nearest polymorphisms were
rs2227311, located 473bp upstream, and rs4151551, located 86bp
downstream of P2RY5. No association with breast cancer risk was
found with rs2227311 (Table 2), and rs4151551 was subsequently
tested in set1. No association with breast cancer risk was found
with rs4151551 (P-heterogeneity¼0.74). We conclude that, if the
Table 2 SNPs genotyped in the study set
SNP Series
Minor allele
frequency
Common
homozygote n (%)
a
Heterozygote n
(%)
a
Rare homozygote n
(%)
a
Number
genotyped P-trend P-het
rs1981434 Cases 0.28 1114 (51) 866 (40) 191 (9) 2171
Controls 0.29 1171 (52) 905 (40) 188 (8) 2264 0.66 0.84
OR (95% CI) 1 (ref) 1.01 (0.89–1.14) 1.07 (0.86–1.33)
rs2854345 Cases 0.19 1309 (65) 631 (31) 66 (3) 2006
Controls 0.18 1489 (68) 625 (29) 77 (3) 2191 0.15 0.12
OR (95% CI) 1 (ref) 1.15 (1.01–1.31) 0.98 (0.70–1.37)
rs520342 Cases 0.25 1121 (56) 759 (38) 126 (6) 2006
Controls 0.25 1232 (57) 793 (36) 149 (7) 2174 0.93 0.56
OR (95% CI) 1 (ref) 1.05 (0.93–1.20) 0.93 (0.72–1.19)
rs399413 Cases 0.29 1032 (51) 819 (41) 164 (8) 2015
Controls 0.27 1157 (53) 855 (39) 164 (8) 2176 0.20 0.42
OR (95% CI) 1 (ref) 1.07 (0.95–1.22) 1.12 (0.89–1.41)
rs4151540 Cases 0.28 1144 (53) 865 (40) 168 (8) 2177
Controls 0.27 1220 (54) 874 (38) 179 (8) 2273 0.63 0.68
OR (95% CI) 1 (ref) 1.06 (0.93–1.19) 1.00 (0.80–1.25)
rs198610 Cases 0.03 1893 (93) 131 (6) 3 (o1) 2027
Controls 0.03 2081 (94) 129 (6) 3 (o1) 2213 0.43 0.69
OR (95% CI) 1 (ref) 1.12 (0.87–1.43) 1.10 (0.22–5.45)
rs2227311 Cases 0.13 1548 (76) 452 (22) 41 (2) 2041
Controls 0.14 1645 (74) 521 (24) 49 (2) 2215 0.25 0.49
OR (95% CI) 1 (ref) 0.92 (0.80–1.06) 0.89 (0.58–1.35)
rs2854344 Cases 0.07 3634 (87) 542 (13) 23 (1) 4199
Controls 0.08 3738 (84) 659 (15) 29 (1) 4426 0.007 0.023
OR (95% CI) 1 (ref) 0.80 (0.75–0.96) 0.82 (0.47–1.41)
rs9535032 Cases 0.29 1020 (50) 830 (41) 180 (9) 2030
Controls 0.29 1134 (51) 884 (40) 189 (9) 2207 0.48 0.76
OR (95% CI) 1 (ref) 1.04 (0.92–1.19) 1.06 (0.85–1.32)
rs425834 Cases 0.03 2052 (94) 135 (6) 5 (o1) 2192
Controls 0.03 2138 (94) 135 (6) 3 (o1) 2276 0.62 0.71
OR (95% CI) 1 (ref) 1.04 (0.81–1.33) 1.74 (0.41–7.28)
rs198580 Cases 0.02 4001 (95) 186 (4) 4 (o1) 4191
Controls 0.03 4187 (94) 251 (6) 3 (o1) 4441 0.018 0.033
OR (95% CI) 1 (ref) 0.78 (0.64–0.94) 1.40 (0.31–6.24)
rs4151611 Cases 0.05 3955 (91) 391 (9) 8 (o1) 4354
Controls 0.04 4160 (91) 387 (8) 7 (o1) 4554 0.38 0.68
OR (95% CI) 1 (ref) 1.06 (0.92–1.23) 1.20 (0.44–3.32)
rs4151620 Cases 0.13 1537 (76) 450 (22) 39 (2) 2026
Controls 0.14 1628 (75) 510 (23) 39 (2) 2177 0.55 0.62
OR (95% CI) 1 (ref) 0.93 (0.81–1.08) 1.06 (0.67–1.66)
rs3092904 Cases 0.26 1118 (55) 785 (38) 139 (7) 2042
Controls 0.26 1227 (56) 822 (37) 154 (7) 2203 0.71 0.75
OR (95% CI) 1 (ref) 1.05 (0.92–1.19) 0.99 (0.78–1.26)
rs4151636 Cases 0.05 1996 (91) 187 (9) 5 (o1) 2188
Controls 0.04 2092 (92) 181 (8) 4 (o1) 2277 0.45 0.71
OR (95% CI) 1 (ref) 1.08 (0.87–1.34) 1.31 (0.35–4.89)
aRounded to the nearest unit. OR, odds ratio; CI, confidence interval.
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to RB1 and not P2RY5 that modifies breast cancer susceptibility.
DISCUSSION
The case–control study design is well suited to the identification of
small-effect genes that are likely to underlie common, complex
diseases such as breast cancer (Risch, 2000). Two approaches have
been proposed. The traditional, hypothesis-driven approach is to
investigate SNPs on the basis of their putative biological relevance,
in particular SNPs in coding regions, as they are more likely to
influence directly the traits under study (Tabor et al, 2002).
Alternatively, when many markers, both coding and noncoding,
are available in a gene, it may be more efficient to select only
tagging SNPs, that is, SNPs that capture the majority of the genetic
variation of the gene (Johnson et al, 2001; Stram et al, 2003a,b;
Thompson et al, 2003). There are no common coding SNPs in the
RB1 gene and since the regulatory SNPs have not yet been
characterised we chose the indirect approach, which allows
detection of association between a particular genomic region and
the disease, whether or not the SNPs themselves have a functional
effect (Gabriel et al, 2002; Cardon and Abecasis, 2003; Zondervan
and Cardon, 2004). We are confident that our set of selected
markers provides enough information about the remainder of the
common SNPs in the gene, and any unknown common variants
will either be tagged by the stSNPs or by the common haplotypes
that they generate (Haiman et al, 2003; The International HAPMAP
Consortium, 2003; Carlson et al, 2004). It is worth noting that the
two SNPs that were associated with breast cancer were not
identified in the EGP resequencing data, and would have been
missed if only these data had been used to select tSNPs.
We found that the minor alleles of two SNPs, rs2854344 and
rs198580 were associated with breast cancer susceptibility at a
nominal significance level of 0.05. However, we have tested 15
SNPs for association and the possibility that the findings are the
result of a Type I statistical error should not be discounted.
Standard adjustments for multiple hypothesis testing, such as the
Bonferroni correction, are too conservative, as they assume that
the tests are independent. We therefore used permutation testing
by randomly shuffling the case–control status to obtain an
empirical adjusted P-value for the most significant association
detected in the primary tests of association (i.e. P-trend¼0.007).
In 1000 random permutations, a P-value at least as significant as
this was obtained on 68 occasions, giving a P-trend adjusted for
multiple testing of 0.068 for the association of rs2854344 with
breast cancer. Thus, the observed association is of borderline
significance.
An alternative explanation for the observed results is confound-
ing due to hidden population stratification. This occurs when allele
frequencies differ between population subgroups and cases and
controls are drawn differentially from those subgroups. However,
it seems unlikely that population stratification is relevant here
because the cases and controls were drawn from the same ethnic
groups (both 498% of northwestern European ancestry).
Furthermore, we have found no evidence for association between
pairs of 64 unlinked markers (2016 tests) in the controls, which
suggests that there is unlikely to be significant substructure in our
population (Goode et al, 2005).
Assuming the results to be real, it may either be due to a direct
causative effect of the SNPs tested, or it may be because they are
markers for other functional variants. The associated SNPs lie in
intron 17 and intron 19 of RB1, and it seems unlikely that either of
them has direct functional effects. pRb undergoes cell-cycle-
dependent phosphorylation during G1, and this modifies its
interaction with at least some members of the E2F family, which
regulates the transcription of many genes required for Sphase
(Kaelin et al, 1992). The finding of protective RB1 alleles was
unexpected, as deletions or inactivating mutations of the gene
observed in tumours generally lead to an absence of negative
control of the protein on the cell proliferation. No coding variants
were identified during EGP resequencing and so it is plausible, but
unlikely that the presence of the still unidentified common variant
prevents the protein from appropriate dephosphorylation. How-
ever, only a small number of subjects were resequenced and it is
possible that the observed association is due to correlation with an
unidentified rare coding variant that was not present in the
resequenced samples. Nor have we been able to identify any
common variants in P2RY5, the gene within intron 17 of RB1 that
might explain the association. Again rare variants cannot be
excluded. The more likely hypothesis is the presence of a SNP in
the promoter or in a regulatory element that affects the level of
pRb. It is possible that the causal variant might induce higher
levels of pRb or expression at critical times than the common
allele.
Further studies would be required to identify and investigate the
mechanism of action of a causative variant. However, before such
studies are contemplated, these putative associations need to be
tested and confirmed in independent breast cancer studies. It
would also be interesting to check the involvement of the
protective alleles in other cancer types, in particular in melanoma,
and in bone, connective tissue, ovarian and uterine cancer which
are also cause of death in retinoblastoma long term survivors (Eng
et al, 1993).
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Table 3 RB1 haplotype analysis using the 15 SNPs genotyped in the study set
Frequency
Haplotype
a Controls Cases OR (95% CI) compared to most common P-value OR (95% CI) compared to all others P-value
000000000000000 0.38 0.37 Ref — 0.94 (0.86–1.03) 0.19
111110000100010 0.16 0.17 1.12 (0.98–1.27) 0.09 1.09 (0.97–1.22) 0.16
000000010000000 0.13 0.13 0.99 (0.86–1.13) 0.86 0.94 (0.83–1.07) 0.33
000000100000000 0.10 0.09 1.01 (0.86–1.18) 0.92 0.97 (0.83–1.12) 0.64
101110001100010 0.07 0.06 0.94 (0.78–1.12) 0.47 0.90 (0.75–1.06) 0.21
Rare
b 0.07 0.08 1.16 (1.03–1.32) 0.02 1.15 (1.02–1.28) 0.02
aSNPs used for haplotype analysis have same order as Table 2. For each SNP, 0 represents the commonest allele and 1 the rarest allele.
bRare haplotypes (p4%) were pooled.
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